Evaluation of high-throughput SARS-CoV-2 serological assays in a longitudinal cohort of mild COVID-19 patients: sensitivity, specificity and association with virus neutralization test

Antonin Bal[1,2], Bruno Pozzetto[3,4], Mary-Anne Trabaud[1], Vanessa Escuret[1,2], Muriel Rabilloud[5,6], Carole Langlois-Jacques[5,6], Adèle Paul[7,8], Nicolas Guibert[7,8], Constance D'Aubarede-Frieh[7,8], Amélie Massardier-Pilonchery[7,8], André Boibieux[9], Florence Morfin-Sherpa[1,2], Virginie Pitiot[8], François Gueyffier[6,10], Bruno Lina[1,2], Jean-Baptiste Fassier[7,8], Sophie Trouillet-Assant[2] COVID SER STUDY GROUP

[1]Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France
[2] CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France
[3]GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), Université Jean Monnet, Lyon University, Saint-Etienne, France
[4]Laboratory of Infectious Agents and Hygiene, University Hospital of Saint-Etienne, Saint-Etienne, France
[5]Université de Lyon, F-69000, Lyon, France; Université Lyon 1, F-69100, Villeurbanne, France; Hospices Civils de Lyon, Pôle Santé Publique, Service de Biostatistique et Bioinformatique, F-69003, Lyon, France
[6] CNRS, UMR 5558, University of Lyon, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, 69100, Villeurbanne, France.
[7] Lyon University, Université Claude Bernard Lyon1, Ifsttar, UMRESTTE, UMR T_9405, 8 avenue Rockefeller Lyon, France
[8] Occupational Health and Medicine Department, Hospices Civils de Lyon, Lyon, France.
[9] Infectious Diseases Department, Hospices Civils de Lyon, Lyon, France.
[10] Pharmacotoxicology Department, Hospices Civils de Lyon, Lyon, France.

Corresponding author: Dr Sophie Trouillet-Assant, Ph.D

Hospices Civils de Lyon, France
Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm,U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 69007, Lyon, France
Phone: + 33 (0)472678780 Email: sophie.assant@chu-lyon.fr

Keywords: COVID-19; SARS-CoV-2; Serological assays; Virus neutralization; Health-care workers

Running title: Performance of SARS-CoV-2 serological assays

Background: The association between SARS-CoV-2 commercial serological assays and virus neutralization test (VNT) has been poorly explored in mild COVID-19 patients.

Methods: A total of 439 specimens were longitudinally collected from 76 healthcare workers with RT-PCR-confirmed COVID-19. Nine serological assays developed by leading global companies (Abbott, DiaSorin, Siemens, Bio-Rad, Wantai, bioMérieux, Euroimmun) were evaluated. For each test the sensitivity to detect SARS-CoV-2 antibodies was determined weekly after symptom onset. Correlation and concordance with the VNT were assessed using the Spearman and Cohen's Kappa coefficients, respectively. Positive percent agreement and negative percent agreement (NPA) were also determined.

Results: The Wantai Total Ab assay targeting the receptor binding domain (RBD) within the S protein presented the best sensitivity at different times during the course of disease. The best correlation between antibody level and neutralizing antibody titer was found with the Euroimmun S1-based IgA assay (Spearman coefficient [95%CI]: 0.71 [0.62-0.79]). A moderate concordance (Kappa [95%CI]: 0.43 [0.23-0.63]) as well as the lowest NPA (33%) was found between the Wantai Total Ab assay and the VNT. Compared to the Wantai Total Ab assay, other total Ab or IgG assays targeting the S or the RBD (bioMérieux, DiaSorin, Siemens,) were more concordant with the VNT (Kappa>0.7 for the three tests) and had a higher NPA (range: 90% to 97%).

Conclusions: Although some assays presented a better concordance with VNT than others, the present findings emphasize that commercialized serological tests including those targeting the RBD cannot substitute a VNT for the assessment of functional antibody response.

Introduction

The evaluation of the humoral immune response to SARS-CoV-2 with serological tests is crucial to further manage the coronavirus disease 2019 (COVID-19) pandemic. Serological testing represents an easy to implement and cost-effective method allowing to rapidly identify individuals exposed to the virus (1,2). Over the last few months, a large number of SARS-CoV-2 commercial assays have been evaluated for their ability to detect specific antibodies (3–9). However, the detection of specific SARS-CoV-2 antibodies does not indicate whether or not the antibodies are functional for neutralizing the virus. In association with the assessment of other immune responses, such as cellular immunity, the determination of neutralizing antibody titer is important to evaluate the protective immunity to SARS-CoV-2 after infection and therefore the risk of reinfection (10–12). To date, the association between SARS-CoV-2 commercial assay results and the presence of neutralizing antibody has been explored in only few studies (13–16). As conflicting findings were reported, it is unclear whether the commercial serological assays would be useful to assess the protective immunity against SARS-CoV-2.

Virus neutralization test (VNT) is considered as the reference to assess the functional ability of antibodies to block the entry of the virus into human cells (17). However, such an assay requires living virus manipulated in a biosafety level 3 (BSL3) facility that needs trained staff and specific equipment, and which is a tedious and time-consuming method. The first study exploring the association of commercial serological assays and VNT claimed that the Wantai Total Ab assay detecting total antibodies directed against the SARS-CoV-2 receptor binding domain (RBD) had the best characteristics to detect functional antibodies at different stages and severity of disease (13). The RBD, within the sub-unit S1 of the spike protein, enables the viral entry into human cells by fixing to the angiotensin-converting enzyme 2 (ACE2) receptor (18). As emphasized by the authors (13), there is an urgent need for further studies

addressing the performance of alternative high-throughput assays in correlation with VNT among persons with mild COVID-19 which is the most common form of the disease.

Thus, the aim of the present study was to evaluate widely-used SARS-CoV-2 serological tests and their potential association with VNT in a cohort of mild COVID-19 patients.

Methods

Study design and sample collection

A prospective longitudinal cohort study was conducted at the laboratory associated with the National reference center for respiratory viruses (University Hospital of Lyon, France)(19). Healthcare workers (HCW) with symptoms suggesting a SARS-CoV-2 infection requiring a RT-PCR test were included. Patients with a positive RT-PCR result at inclusion (V1) returned weekly for 6 additional visits (V2-V7). Serum samples were collected at each visit. Written informed consent was obtained from all participants; ethics approval was obtained from the national review board for biomedical research in April 2020 (*Comité de Protection des Personnes Sud Méditerranée I*, Marseille, France; ID RCB 2020-A00932-37), and the study was registered on ClinicalTrials.gov (NCT04341142). A total of 439 serum specimens were longitudinally collected from 76 HCW. Among them, 74 had mild COVID-19 related symptoms (fever, cough, loss of taste or smell, diarrhea etc) and did not require hospital admission. Two out of 76 HCW were admitted to the hospital (not in intensive care unit) due to the severity of their symptoms. Among the 439 collected samples, 170 of them taken at V2, V4, V7 from 56 patients were tested by VNT.

Virological investigation

COVID-19 diagnosis at inclusion was performed by RT-PCR on nasopharyngeal swab using the cobas SARS-CoV-2 assay (Roche, Basel, Switzerland).

A total of 9 serological assays developed by leading global companies in the field (Abbott, DiaSorin, Siemens, Bio-Rad, Wantai, bioMérieux, Euroimmun) were investigated according to the protocol recommended by each manufacturer (characteristics are summarized in Table 1). Positivity was established according to threshold value recommended by each manufacturer. As previously suggested, we also evaluated a cut-off (OD ratio ≥ 10) to indicate the presence of protective antibodies for the Wantai Total Ab assay (13).

A plaque reduction neutralization test (PRNT) was used for the detection and titration of neutralizing antibodies, as previously described (20). Briefly, a ten-fold dilution of each serum specimen in culture medium (Dulbecco's Modified Eagle Medium containing antibiotics and 2% foetal calf serum) was first heated for 30 min at 56°C to avoid complement-linked reduction of the viral activity. Serial two-fold dilutions (tested in duplicate) of the serum specimens in culture medium were mixed at equal volume with the live SARS-CoV2 virus. After gentle shaking and a contact of 30 minutes at room temperature in plastic microplates, 150 µL of the mix was transferred into 96-well microplates covered with Vero E6 cells. The plates were incubated at 37°C in a 5% CO_2 atmosphere. The reading was evaluated microscopically 5 to 6 days later when the cytopathic effect of the virus control reached 100 $TCID_{50}$/150 µL. Neutralization was recorded if more than 50% of the cells present in the well were preserved. The neutralizing titer was expressed as the inverse of the higher serum dilution that exhibited neutralizing activity; a threshold of 20 was used ($PRNT_{50}$ titer ≥ 20). All experiments were performed in a BSL3 laboratory. The comparison of this VNT with a standardized assay using retroviruses pseudo-typed with the SARS-CoV-2 S viral surface protein found a high correlation and concordance (20).

Statistical analyses

For each test the clinical sensitivity was determined weekly after symptom onset. The correlation and concordance with the VNT were assessed using the Spearman and Cohen's Kappa coefficients, respectively. The concordance was classified as slight (Cohen's Kappa coefficient, [0-0.2]), fair [0.21-0.4], moderate [0.41-0.6], substantial [0.61-0.8], and almost perfect [0.81-1] according to Landis and Koch criteria (21). The Cohen's Kappa coefficient was not interpreted if the sensitivity was 100%. The positive and negative percentage agreements (PPA, NPA) were also determined as previously described (22). The estimation of the correlation coefficient was not performed due to an upper limit of signal to cut-off ratio for the Siemens and Bio-Rad assays. Specificity was assessed with 30 pre-pandemic serum specimens collected from healthy donors in 2019. The estimates are given with their bilateral 95% confidence interval (CI) calculated using the Wilson method. The 95% CI for Cohen's Kappa coefficient was calculated using the bootstrap percentile method. The paired comparison of sensitivity between two assays was performed with the non-parametric McNemar test. A p-value < 0.05 was considered as statistically significant.

Results

Sensitivity and specificity

During the first week after the onset of symptoms the sensitivity for the detection of SARS-CoV-2 antibodies ranged from 6.6% (DiaSorin, Liaison) to 25.0% (Euroimmun). The second week the sensitivity was greater than 70% for three tests including Bio-Rad, Wantai Total Ab, and Euroimmun assays (74.2%, 79.0% and 72.6%, respectively). The highest of sensitivity was found at week # 3 for Bio-Rad (96.6%), Wantai Total Ab (100%), Wantai IgM (94.9%), bioMérieux IgM (78.0%) and Euroimmun (96.6%), at week # 4 for Abbott (93.2%), and at week # 6 for DiaSorin (93.2%), Siemens (98.3%) and bioMérieux IgG (94.9%). After this point, a decrease of sensitivity was noted for all assays except for the Wantai Total Ab which remained steady at 100% over the course of the disease (Table 1). Compared to the Wantai Total Ab assay, the differences were significant before 14 days post-symptom onset with all other assays, except with the Euroimmun and Bio-Rad assays; after 14 days post-symptom onset, the differences were significant with all other assays.

Regarding specificity, no false positive result was found using 30 pre-pandemic sera, although 3 samples gave a borderline index (between 0.8 and 1.1) with the Euroimmun IgA assay (supplementary Table 1).

Kinetics of neutralizing antibody titers

The neutralizing capacity of antibodies was determined at three time points for 56 patients (n=170 samples). No neutralizing antibody was detected in 42.0% (21/50), 5.8% (3/51), and 8.7% (6/69) of samples collected between, respectively, 1-14, 15-28, and more than 28 days after symptom onset. For the samples with a detection of neutralizing antibody (n=140), the median [IQR] titer was 60 [40-100] between 1-14 days post symptom, reached 80 [60-120]

between 15-28 days post symptom and decreased in samples collected after more than 28 days (median: 60 [40-120]).

Comparison of results between commercial kits and VNT

The best correlation between commercial kits and VNT was found with the Euroimmun S1-based IgA assay (Spearman coefficient [95%CI]: 0.71 [0.62-0.79]) while the Abbott N-based assay presented the lowest correlation (0.47 [0.33-0.60]; Figure 1, Table 2).

A slight and fair concordance with VNT were noticed for the 2 IgM assays evaluated herein (Kappa [95%CI]: 0.24 [0.14-0.36] for bioMérieux IgM and 0.40 [0.21-0.58] for the Wantai IgM assays). Regarding total Ab or IgG assays targeting the S protein, three had substantial concordance with VNT (Kappa [95%CI]: 0.71[0.57-0.84] for bioMérieux, 0.70 [0.56-0.83] for DiaSorin, and 0.72 [0.55-0.85] for Siemens assays) while the concordance with the Wantai Total Ab assay was moderate (0.43 [0.23-0.63]; Table 2). The NPA with VNT ranged from 33.3% [21.1-48.3] for the Wantai Total Ab assay to 96.8% [86.8-99.3] for the DiaSorin and was < 90% for 7/9 assays. The PPA with VNT was > 90% for all tests except the DiaSorin and the two IgM based assays (Wantai and bioMérieux) (Table 2).

For the Wantai Total Ab assay we evaluated a cut-off (OD ratio ≥ 10) to indicate the presence of neutralizing antibody. For the samples with no detection of neutralizing antibody (n=30), 20 had a positive Wantai Total Ab but only 2 had an OD ratio ≥ 10. Of note, 9/20 samples with no detection of neutralizing antibody and a positive Wantai Total Ab were collected more than 14 days post symptom onset. Among the samples with a detection of neutralizing antibody (n=140), a total of 39 (28%) had an OD ratio < 10 with the Wantai Total Ab assay. The titer of neutralizing antibody for these 39 samples was low (range: 20-50).

Discussion

In a longitudinal study of 76 HCW with RT-PCR-confirmed COVID-19, we found that the Wantai Total Ab assay had the best sensitivity over the course of the disease. In particular, the sensitivity reached and remained at 100% as soon as week # 3 post symptom onset. This finding observed in mild COVID-19 patients is consistent with previous reports of excellent sensitivity of this test notably in severe patients (3,13).

In addition to the sensitivity for the detection of SARS-CoV-2 antibodies, the ability of a commercial test to assess the protective immunity against SARS-CoV-2 needs to be determined. With this aim, Tang et al. compared three commercial assays (Roche Total Ab, Abbott IgG, both tests targeting the N protein, and Euroimmun IgG assays targeting the S protein) to VNT on 67 specimens (14). They found that NPA was poor, ranging from 56% for Roche to 81% for Euroimmun, making them imperfect proxies for neutralization. These findings are highly consistent with those of the present study that found the lowest NPA for the Wantai Total Ab assay (33%) and a NPA below 90% for all tests except for bioMérieux IgG and DiaSorin. Furthermore, the concordance between VNT and the Wantai Total Ab assay was only moderate while the concordance was substantial with bioMérieux IgG, DiaSorin, Siemens, Abbott, Euroimmun and Bio-Rad. The low NPA and moderate concordance noticed for the Wantai Total Ab might be partially explained by the excellent ability of this test to detect RBD-specific antibodies at the very early phase of infection, irrespective of their neutralizing properties in line with the delay required for antibody maturation (23). In the first study comparing VNT with commercialized tests, the authors found that the Wantai Total Ab assay had the best characteristics to detect functional antibodies in different stages and severity of disease (13). However the median interval between the onset of symptoms and sample collection was 43 days for the mild patients samples tested (n=71 samples). Thus, the antibodies could be detected with both the Wantai

Total Ab and the VNT assay at this time. As the authors used VNT as the gold-standard for sensitivity assessment, this might explain the difference in findings with the present study (13). In addition, we confirmed that the PPA with VNT was high for most of the serological assays evaluated herein (14–16). Nevertheless, the NPA should be considered as one of the most relevant statistical parameter to avoid misinterpretation regarding the association of commercial serological assays and VNT.

Furthermore, as previously reported by others (23–25), not all RBD-binding antibodies have neutralizing properties which is consistent with that reported herein regarding the RBD-based assays that do not have perfect concordance with VNT. Conversely, antibodies targeting a region other than the S protein may have functional activity, as previously reported (17,26–28). In the present study, the Abbott and Bio-Rad assays directed against the N protein presented a substantial concordance with VNT. N-directed and RBD-neutralizing antibodies can be produced concomitantly over the course of the disease which can also explain this finding.

In addition to the different targeted antigens, the heterogeneity in assay performance found herein could be related to various factors including the detected isotypes. Moreover, antibody levels may also be very different according to the time since symptom onset and according to clinical severity of the disease (29). Herein, serum samples were collected longitudinally from disease diagnosis enabling to explore the early phase of the antibody response in a cohort of HCW, which constitutes one of the main strength of the present study.

The present study does, however, have certain limitations. For instance, specificity was not been extensively studied; yet the Euroimmun IgA assay seemed to have the worst specificity, which is consistent with previous studies reporting a lack of specificity for this assay (5,6,13). In addition, the performance of other notable commercial assays such as Euroimmun IgG or Roche Ig Total were not assessed. Second, not all the samples were systematically tested by

VNT, in-line with the labor-intensive nature of this method. Finally, the size of the tested population remains small, which limits the extrapolation of the results, although the present study represents the largest one comparing VNT to other serological tests through a longitudinal design.

The results presented herein obtained from mild COVID-19 patients confirm that, for exposure assessment, the Wantai Total Ab assay should be preferred to other commercial kits due to a very high sensitivity. For evaluating protective immunity, the Wantai Total Ab assay with an optimized cut-off or other tests targeting the S protein as Siemens, DiaSorin or bioMérieux IgG could be more useful, notably to screen serum specimens candidate for the presence of neutralizing antibodies. However, these tests or others cannot substitute a VNT for assessing functional antibody response; neutralizing assays remain the gold standard and easy-to-use tests, such as those based on pseudoviruses (6,20,30), should be developed and standardized. Furthermore, the recent development of surrogate virus neutralization tests based on antibody-mediated blockage of the interaction between ACE-2 receptor and the RBD is very promising as they were designed in an ELISA format enabling high-throughput testing (24,31).

In conclusion, the present study provides original data concerning the performance of widely-used serological tests, which could help diagnostic laboratories in the choice of a particular assay according to the intended use.

COVID-SER study group

Adnot Jérôme, Alfaiate Dulce, Bal Antonin, Bergeret Alain, Boibieux André, Bonnet Florent, Bourgeois Gaëlle, Brunel-Dalmas Florence, Caire Eurydice, Charbotel Barbara, Chiarello Pierre, Cotte Laurent, d'Aubarede Constance, Durupt François, Escuret Vanessa, Fascia Pascal, Fassier Jean-Baptiste, Fontaine Juliette, Gaillot-Durand Lucie, Gaymard Alexandre, Gillet Myriam, Godinot Matthieu, Gueyffier François, Guibert Nicolas, Josset Laurence, Lahousse Matthieu, Lina Bruno, Lozano Hélène, Makhloufi Djamila, Massardier-Pilonchéry Amélie, Milon Marie-Paule, Moll Frédéric, Morfin Florence, Narbey David, Nazare Julie-Anne, Oria Fatima, Paul Adèle, Perry Marielle, Pitiot Virginie, Prudent Mélanie, Rabilloud Muriel, Samperiz Audrey, Schlienger Isabelle, Simon Chantal, Trabaud Mary-Anne, Trouillet-Assant Sophie

Acknowledgements

We thank all the personnel of the occupational health and medicine department of Hospices Civils de Lyon who contributed to the samples collection. We thank Lucie Charreton and Khadija Sfouli for their excellent work concerning serological testing, all the technicians from the virology laboratory whose work made it possible to obtain all these data, as well as Amira Lachekhab and Naima Rolnin for their technical assistance. We thank Karima Brahima and all members of the clinical research and innovation department for their reactivity (DRCI, Hospices Civils de Lyon). We thank Philip Robinson (DRCI, Hospices Civils de Lyon) for his help in manuscript preparation.

Author contributor's statement

All authors were involved in the analysis and interpretation of data as well as drafting the manuscript or revising it critically for important intellectual content. AB, BP, VP, FG, JBF and STA made substantial contributions to the conception and design of the study and designed the experiments. BP performed VNT. MAT and VE performed the serological assay

experiments. NG, AP, CA, AMP, AB, and JBF were involved in patient care, VP performed the data collection, STA, AB, MA and BP performed the data analysis. MR and CLJ performed the statistical analysis. AB and STA wrote the paper, BL, BP, JBF, AP, VE and MAT revised the manuscript content. All authors read and approved the final manuscript.

Conflict interests statement

Antonin Bal has received grant from bioMérieux and has served as consultant for bioMérieux for work and research not related to this manuscript. Sophie Trouillet-Assant has received research grant from bioMérieux concerning previous works not related to this manuscript. The other authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

Funding

This research is being supported by Hospices Civils de Lyon and by Fondation des Hospices Civils de Lyon.

References

1. Krammer F, Simon V. Serology assays to manage COVID-19. Science. 2020;368:1060–1.

2. Winter AK, Hegde ST. The important role of serology for COVID-19 control. Lancet Infect Dis. 2020;20:758–9.

3. Trabaud M-A, Icard V, Milon M-P, Bal A, Lina B, Escuret V. Comparison of eight commercial, high-throughput, automated or ELISA assays detecting SARS-CoV-2 IgG or total antibody. J Clin Virol. 2020;132:104613.

4. Van Elslande J, Decru B, Jonckheere S, Van Wijngaerden E, Houben E, Vandecandelaere P, et al. Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by 4 automated immunoassays and 3 ELISAs. Clin Microbiol Infect. 2020;

5. Van Elslande J, Houben E, Depypere M, Brackenier A, Desmet S, André E, et al. Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients. Clin Microbiol Infect. 2020;26:1082–7.

6. Meyer B, Torriani G, Yerly S, Mazza L, Calame A, Arm-Vernez I, et al. Validation of a commercially available SARS-CoV-2 serological immunoassay. Clin Microbiol Infect. 2020;

7. Theel ES, Harring J, Hilgart H, Granger D. Performance Characteristics of Four High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2. J Clin Microbiol. 2020;58.

8. Lisboa Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui L-P, Johnston JC, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020;370:m2516.

9. National SARS-CoV-2 Serology Assay Evaluation Group. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis. 2020;

10. Addetia A, Crawford KH, Dingens A, Zhu H, Roychoudhury P, Huang M, et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate. medRxiv. Cold Spring Harbor Laboratory Press; 2020;2020.08.13.20173161.

11. Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. Sci Immunol. 2020;5.

12. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun. 2020;11:4704.

13. GeurtsvanKessel CH, Okba NMA, Igloi Z, Bogers S, Embregts CWE, Laksono BM, et al. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat Commun. 2020;11:3436.

14. Tang MS, Case JB, Franks CE, Chen RE, Anderson NW, Henderson JP, et al. Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays. Clin Chem. 2020;

15. Jääskeläinen AJ, Kuivanen S, Kekäläinen E, Ahava MJ, Loginov R, Kallio-Kokko H, et al. Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation. J Clin Virol. 2020;129:104512.

16. Suhandynata RT, Hoffman MA, Huang D, Tran JT, Kelner MJ, Reed SL, et al. Commercial Serology Assays Predict Neutralization Activity Against SARS-CoV-2. Clin Chem. 2020;

17. Jiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends Immunol. 2020;41:355–9.

18. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–3.

19. Trouillet-Assant et al. Assessment of Serological Techniques for Screening Patients Regarding COVID-19 (COVID-SER): a prospective multicentric study. BMJ open 2020 In press.

20. Legros V, Denolly S, Vogrig M, Boson B, Rigaill J, Pillet S, et al. A longitudinal study of SARS-CoV-2 infected patients shows high correlation between neutralizing antibodies and COVID-19 severity. medRxiv. Cold Spring Harbor Laboratory Press; 2020;2020.08.27.20182493.

21. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.

22. Obermeier P, Muehlhans S, Hoppe C, Karsch K, Tief F, Seeber L, et al. Enabling Precision Medicine With Digital Case Classification at the Point-of-Care. EBioMedicine. 2016;4:191–6.

23. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584:115–9.

24. Tan CW, Chia WN, Qin X, Liu P, Chen MI-C, Tiu C, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020;38:1073–8.

25. Perera RA, Mok CK, Tsang OT, Lv H, Ko RL, Wu NC, et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill [Internet]. 2020 [cited 2020 Oct 21];25. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189648/

26. Tong P-B-V, Lin L-Y, Tran TH. Coronaviruses pandemics: Can neutralizing antibodies help? Life Sci. 2020;255:117836.

27. Ho M. Perspectives on the development of neutralizing antibodies against SARS-CoV-2. Antib Ther. 2020;3:109–14.

28. Cohen SA, Kellogg C, Equils O. Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development. Hum Vaccin Immunother. 2020;1–4.

29. Rijkers G, Murk J-L, Wintermans B, van Looy B, van den Berge M, Veenemans J, et al. Differences in antibody kinetics and functionality between severe and mild SARS-CoV-2 infections. J Infect Dis. 2020;

30. Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020;9:680–6.

31. Byrnes JR, Zhou XX, Lui I, Elledge SK, Glasgow JE, Lim SA, et al. A SARS-CoV-2 serological assay to determine the presence of blocking antibodies that compete for human ACE2 binding. medRxiv [Internet]. 2020 [cited 2020 Sep 29]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273274/

Manufacturer (platform)	**Abbott (Architect)**	**DiaSorin (Liaison®)**	**Siemens (Atellica®)**	**Bio-Rad**	**Wantai**		**bioMérieux (Vidas®)**		**Euroimmun**
Assay name	SARS-CoV-2 IgG	SARS-CoV-2 S1/S2 IgG	SARS-CoV-2 Total	Platelia SARS-CoV-2 Total Ab	SARS-CoV-2 Total Ab	SARS-CoV-2 IgM	SARS-CoV-2 IgG	SARS-CoV-2 IgM	SARS-CoV-2 IgA
Assay type	CMIA	CLIA	CLIA	ELISA	ELISA	ELISA	ELFA	ELFA	ELISA
Antigen	N	S1+S2	RBD	N	RBD	RBD	RBD	RBD	S1
Sensitivity vs SARS-CoV-2 RT-PCR [95%CI]									
days after symptom onset (n)									
[1-7] (61)	9.84 [5.17-17.91]	6.56 [2.98-13.83]	6.56 [2.98-13.83]	18.03 [11.35-27.43]	22.95 [15.36-32.84]	13.11 [7.55-21.81]	8.20 [4.05-15.90]	11.48 [6.34-19.88]	25.00 [17.02-35.14]
[8-14] (63)	59.68 [49.23-69.31]	32.26 [23.41-42.59]	41.94 [32.18-52.37]	74.19 [64.18-82.19]	79.03 [69.41-86.23]	64.52 [54.11-73.71]	39.68 [30.17-50.04]	49.21 [39.09-59.38]	72.58 [62.47-80.81]
[15-21] (59)	91.53 [83.60-95.81]	83.05 [73.61-89.59]	89.83 [81.52-94.65]	96.61 [90.26-98.87]	100.00 [95.62-100.00]	94.92 [87.94-97.95]	86.44 [77.50-92.19]	77.97 [67.97-85.50]	96.61 [90.26-98.87]
[22-28] (59)	93.22 [85.73-96.92]	86.44 [77.50-92.19]	93.22 [85.73-96.92]	94.92 [87.94-97.95]	100.00 [95.62-100.00]	89.83 [81.52-94.65]	93.22 [85.73-96.92]	69.49 [58.96-78.32]	91.53 [83.60-95.81]
[29-35] (65)	86.15 [77.66-91.76]	92.31 [85.03-96.21]	93.85 [86.98-97.21]	92.19 [84.81-96.15]	100.00 [96.00-100.00]	84.62 [75.89-90.58]	90.77 [83.13-95.15]	52.31 [42.23-62.20]	84.62 [75.89-90.58]
[36-42] (59)	89.83 [81.52-94.65]	93.22 [85.73-96.92]	98.31 [92.75-99.62]	91.53 [83.60-95.81]	100.00 [95.62-100.00]	88.14 [79.49-93.44]	94.92 [87.94-97.95]	45.76 [35.51-56.38]	88.14 [79.49-93.44]
[43-85] (73)	89.04 [81.58-93.71]	89.04 [81.58-93.71]	95.89 [90.15-98.35]	88.89 [81.34-93.62]	100.00 [96.38-100.00]	81.94 [73.38-88.20]	87.67 [79.97-92.68]	43.84 [34.67-53.44]	79.45 [70.69-86.11]

Table 1 – Sensitivity of 9 SARS-CoV-2 commercial serological assays. Positivity was established according to threshold value recommended by each manufacturer. Ab: antibodies, Ig: immunoglobulin, ELISA: enzyme-linked immunosorbent assay, CMIA: chemiluminescence microparticule immune assay CLIA: chemiluminescence immune assay, ELFA: enzyme-linked fluorescent assay, n: number of samples, CI: confidence interval.

Manufacturer (platform)	**Abbott (Architect)**	**DiaSorin (Liaison®)**	**Siemens (Atellica®)**	**Bio-Rad**	**Wantai**		**bioMérieux (Vidas®)**		**Euroimmun**
Assay name	SARS-CoV-2 IgG	SARS-CoV-2 S1/S2 IgG	SARS-CoV-2 Total	Platelia SARS-CoV-2 Total Ab	SARS-CoV-2 Total Ab	SARS-CoV-2 IgM	SARS-CoV-2 IgG	SARS-CoV-2 IgM	SARS-CoV-2 IgA
Assay type	CMIA	CLIA	CLIA	ELISA	ELISA	ELISA	ELFA	ELFA	ELISA
Antigen	N	S1+S2	RBD	N	RBD	RBD	RBD	RBD	S1
Concordance with virus VNT - Cohen's Kappa coefficient [95%CI]									
Overall (n=170)	0.64 [0.49-0.79]	0.70 [0.56-0.83]	0.72 [0.55-0.85]	0.62 [0.44-0.76]	0.43 [0.23-0.63]	0.40 [0.21-0.58]	0.71 [0.57-0.84]	0.24 [0.14-0.36]	0.61 [0.43-0.76]
<14 dps	0.70 [0.45-0.88]	0.41 [0.19-0.60]	0.68 [0.45-0.84]	0.69 [0.45-0.86]	0.46 [0.21-0.67]	0.61 [0.35-0.79]	0.41 [0.29-0.76]	0.52 [0.27-0.72]	0.60 [0.35-0.79]
>14 dps	0.40 [-0.06-0.72]	0.86 [0.65-1]	0.51 [0-0.89]	0.45 [-0.05-0.79]	NA	0.08 [-0.09-0.35]	0.90 [0.71-1.00]	0.18 [0.02-0.25]	0.55 [0.06-0.81]
Correlation between Ab level and neutralizing Ab titer									
Spearman coefficient [95%CI]	0.47 [0.33-0.60]	0.53 [0.39-0.65]	NA	NA	0.56 [0.43-0.66]	0.54 [0.40-0.65]	0.61 [0.49-0.71]	0.50 [0.32-0.65]	0.71 [0.62-0.79]
Negative and Positive Percent Agreement with VNT									
NPA [95%CI]	74.2 [59.7-84.8]	96.8 [86.8-99.3]	80.7 [66.7-89.7]	61.3 [46.6-74.2]	33.3 [21.1-48.3]	56.7 [41.9-70.4]	90.3 [78.1-96.1]	83.9 [70.4-91.9]	67.7 [53.0-79.6]
PPA [95%CI]	92.1 [87.6-95.1]	87.9 [82.6-91.7]	93.6 [89.3-96.2]	95.7 [91.9-97.8]	99.3 [96.9-99.9]	86.4 [81.0-90.5]	90.1 [85.1-93.5]	57.4 [50.5-64.1]	92.9 [88.4-95.7]

Table 2 – Association of SARS-CoV-2 commercial serological and a virus neutralization test. Ab: antibodies, Ig: immunoglobulin, ELISA: enzyme-linked immunosorbent assay, CMIA: chemiluminescence microparticule immune assay CLIA: chemiluminescence immune assay, ELFA: enzyme-linked fluorescent assay, n: number of samples, CI: confidence interval, dps: days post onset of symptoms, test. VNT: Virus neutralization test.

Figure 1 legend

Correlation between SARS-CoV-2 neutralizing antibody titers and antibodies level determined by SARS-CoV-2 commercial serological assays. Magenta dots indicate sample collected ≤14 days post onset of symptoms (dps), orange dots indicate samples collected from 14-28 dps, green dots indicate specimen collected more than 28 dps. Spearman correlation coefficients and 95% confidence interval are indicated. All p-values were < 0.001.















- 1-14 dps
- 15-28 dps
- > 28 dps